The firm says the round provides 'a strong vote of confidence' in TransAlgae’s disruptive microalgae-based oral delivery tech.

The Jerusalem-based developer of oral drug delivery systems hopes to revolutionize the treatment of Type 1 and Type 2 diabetes.